<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903990</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190505</org_study_id>
    <secondary_id>2019-A00703-54</secondary_id>
    <nct_id>NCT04903990</nct_id>
  </id_info>
  <brief_title>Circulating Fetal Cells and Breast Cancer</brief_title>
  <acronym>MoSaiC2</acronym>
  <official_title>Fetal Microchimerism and Fetal Stem Cells in Breast Cancer: Analysis of Circulating Fetal Cell Sub-populations in Women With Breast Cancer. CIRCULATING FETAL CELLS AND BREAST CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruban Rose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After pregnancy, fetal cells remain in a woman's body for years. These cells may be involved&#xD;
      in different physiological situations (e.g. wound healing) and diseases (e.g. cancer).The&#xD;
      study will evaluate the level of circulating fetal immune cells in patients with breast&#xD;
      cancer vs controls with benign breast tumors, and further characterize these fetal cells.&#xD;
      Patients participation will be limited to accepting that an additional blood sample is&#xD;
      collected on the day of their preop consultation and blood test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most common cancer in the female population. The protective mechanism&#xD;
      associated with pregnancy is not fully understood.&#xD;
&#xD;
      During pregnancy fetal cells cross the placental barrier and may remain in the maternal&#xD;
      circulation even for up to 30 years after childbirth. This phenomenon is called fetal&#xD;
      microchimerism.&#xD;
&#xD;
      The presence of circulating fetal cells would have a protective role against breast cancer.&#xD;
      However, their phenotype and role in the anti-tumor response is not explored.&#xD;
&#xD;
      The objective of the study is to identify the sub-population (s) of circulating fetal immune&#xD;
      cells that may have an impact on the processes of carcinogenesis in breast cancer, in the&#xD;
      context of fetal microchimerism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of fetal cells in each immune cell subpopulation.</measure>
    <time_frame>3 years</time_frame>
    <description>Using fluorescence activated cell sorting method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation markers.</measure>
    <time_frame>3 years</time_frame>
    <description>Using immunocytochemistry method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytotoxicity markers.</measure>
    <time_frame>3 years</time_frame>
    <description>Using immunocytochemistry method.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>women 18-50 years&#xD;
with previous history of a male birth&#xD;
scheduled for malignant breast tumor surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>women 18-50 years&#xD;
with previous history of a male birth&#xD;
scheduled for benign breast tumor surgery&#xD;
or cancer free</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample for quantification and characterization of fetal blood stem cells.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes only women who have had a male child, premenopausal, aged&#xD;
        18-50 years, who are operated on for breast cancer or who have just been diagnosed with&#xD;
        breast cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women aged 18-50&#xD;
&#xD;
          -  having had a male child&#xD;
&#xD;
          -  informed and not having objected to participating in the research.&#xD;
&#xD;
        Patients:&#xD;
&#xD;
        - having a diagnosis of breast cancer&#xD;
&#xD;
        Controls:&#xD;
&#xD;
          -  operated on for benign breast tumors&#xD;
&#xD;
          -  cancer free&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  autoimmune disease&#xD;
&#xD;
          -  immunomodulatory treatment&#xD;
&#xD;
          -  history of cancer other than breast cancer&#xD;
&#xD;
          -  ongoing hormonal treatment&#xD;
&#xD;
          -  women not affiliated to the social security&#xD;
&#xD;
          -  under AME (state medical aid)&#xD;
&#xD;
          -  under tutorship / curatorship&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nathalie CHABBERT-BUFFET, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de Tenon-Service de Gynécologie Obstétrique et Médecine de la Reproduction</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Microchimerism</keyword>
  <keyword>Hematopietic fetal cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

